PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Büller, Harry R.
TI  - Oral Rivaroxaban Alone for Symptomatic Pulmonary Embolism
DP  - 2012 Jun 01
TA  - MD Conference Express
PG  - 21--22
VI  - 12
IP  - 4
4099  - http://mdc.sagepub.com/content/12/4/21.short
4100  - http://mdc.sagepub.com/content/12/4/21.full
AB  - Rivaroxaban, a direct, specific, competitive factor Xa inhibitor that inhibits thrombin generation, is an effective treatment for venous thromboembolism. The Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism trial [EINSTEIN PE; Buller HR et al. N Engl J Med 2012] reported data that showed that rivaroxaban was noninferior to standard therapy but had a superior bleeding profile in patients with pulmonary embolism.